Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oyster Point Pharma Inc. OYST

Healthcare Biotechnology
Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.


NDAQ:OYST - Post by User

Oyster Point Pharma Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Post by HDavison Oct 18, 2021 1:50pm
50 Views
Post# 34018974

OYST - FDA

OYST - FDA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities